Abstract:Background: Metabolic dysfunction associated steatotic liver disease (MASLD) is the most prevalent liver disease worldwide with an estimated 25% of U.S. adults having MASLD. MASLD is typically regarded as a diet driven disease, with the Western diet (high fat, high sugar, low fiber) being a major driver. Recently, evidence suggests MASLD can be present regardless of body weight. There is not good evidence on how prevalent this is, but reports suggest it could be as high as nearly 30% of MASLD patients. As such, there is a critical need to better understand MASLD independent of weight to ensure all individuals with the disease are receiving proper diagnosis and treatment. Methods: Young female rats were fed either a Control (AIN-93G) or Western (45% fat, 34% sugar) diet for 8 weeks. Histology, RT-qPCR, and standard biological assays were performed to analyze differences in hepatic function and fatty acid analysis was used to analyze fatty acid deposition in the liver, adipose tissue, and brain. Results: There were no statistically significant differences in the weights of rats consuming a Control or Western diet. However, consuming a Western diet had increased histological evidence of fat deposition and inflammation compared to Control. Rats consuming a Western diet also displayed increased ( p<0.05) hepatic triglyceride content and relative expression of several key genes involved in lipogenesis and oxidative stress. Fatty acid analysis found Western diet rats to have increased (p<0.05) hepatic monounsaturated fatty acid (MUFA) content, while adipose tissue of those same animals had decreased (p<0.05) MUFAs. Conclusions: The Western diet plays a significant role in the development of MASLD independent of differences in weight. This model may serve to better elucidate mechanisms at play in lean MASLD. We are currently conducting additional experiments on the role of alcohol in this phenomenon. WVU Davis College Dean's Opportunity Fund and the UVM Food Systems Research Center. This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease

Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges

Rodent model of metabolic dysfunction‐associated fatty liver disease: a systematic review

Novel insights into metabolic‐associated steatotic liver disease preclinical models

Updated mechanisms of MASLD pathogenesis

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics

Applying Proteomics in Metabolic Dysfunction-Associated Steatotic Liver Disease: from Mechanism to Biomarkers

Molecular pathogenesis of metabolic dysfunction‐associated steatotic liver disease, steatohepatitis, hepatic fibrosis and liver cirrhosis

Mechanism of Metabolic Dysfunction-associated Steatotic Liver Disease: Important role of lipid metabolism

Ex Vivo Tools and Models in MASLD Research

Comparison of Animal Models for the Study of Nonalcoholic Fatty Liver Disease

Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease

Metabolic-Dysfunction Associated Liver Disease Progresses Independent of Weight in a Rodent Model

Pathogenesis of and Major Animal Models Used for Nonalcoholic Fatty Liver Disease

Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications

Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions

Rodent Models of Nonalcoholic Fatty Liver Disease

Induction of steatosis in primary human hepatocytes recapitulates key pathophysiological aspects of metabolic dysfunction-associated steatotic liver disease